bjh12215-sup-0001-FigS1.tiffTIFF image1056KFig S1. Responses to NVP-AUY922-AG in primary AML cells in vitro and their distribution with (A) age, (B) sex, (C) FAB group, (D) de novo or secondary AML, E) LD50′s of primary AML cells with FLT3 or NPM1 mutations or combinations of these when treated with NVP-AUY922-AG (F) presenting white blood count. (G) LD50 of AML primary samples and primary non-leukaemia samples to NVP-AUY922-AG.
bjh12215-sup-0002-Figurelegend.docWord document22K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.